Revive Therapeutics Ltd C.RVV

That 31st site wasn't the winner!

[1ottrunner]

Just 1 patient per day per site would have this trial done in less than 20 days.
Plus 60 days for data colelction and evaluation.

By now the initial data, and dose must be selected

OR

the data is too close to call, MF wants to push through the trial anyway...hey...it might lead to another round of sweet financing or a partnership with one of other companies he and his buddies are creating to fleece investors.

hmmm.

Let's see, Revive, Pharmala, Psyched Wellness, Australis etc.

[Trippedstocks]

they want to complete the 1000 participants so they have the appropriate information for the next phase 3 study.... Infectious Diseases including COVID-19.... Bucillamine patent goes beyond one virus...

[1ottrunner]

You can't have a successfully trial in an IND and transfer it to another. thus, false. Show me the Gout data. Start there.  

[1ottrunner]

By data I mean dollars.  Show me the sales RVV has accumulated on the positive Gout results I've 'heard' about.

[Trippedstocks]

you can transfer trial data and use it as supporting documentation. How was the Phase 2 portion of the Bucillamine in mild to moderate covid completely skipped? How was a phase 1 skipped? How did they get to a phase 3 with no pre-clinical research? They had supporting safety and efficacy information of sufficient value to consider that information as equivalent to phase 1, 2 and pre-clinical

[1ottrunner]

So you believe RVV will attempt flu next, maybe pneumonia. If the data on Covid was good I would agree.  Might as well.  

[RandomGuy1]

This post has been removed in accordance with Community Policy

[cool888]

[RandomGuy1]

This post has been removed in accordance with Community Policy

[Trippedstocks]

pneumonia is a symptom of a viral, bacterial, or fungal infection. They would be targeting viruses with a similar structure and that cause similar symptoms.

[1ottrunner]

The same method of action, thiol groups, has been shown effective against pneumonia. It isn't just a viral issue.

[Trippedstocks]

I guess most infectious Diseases would be the goal. Pneumonia included then. Depends what falls under a disease I guess. if results are good It's a multi billion dollar drug within a short period. Depends on results. But to truly back up infectious Diseases patent they will need the study completed or DSMB to declare it good and call the study done

[1ottrunner]

As you say, depends on results. Why no word on dosage?  The split should have taken place.

[Towser7]

I've been long on this but does anyone honestly think anyone will care when the results come out?  I don't even think it will be more than a blip in the news cycle.  Unlike Gilead there's been almost zero coverage of this.  This stock has reminded me that having a good product and being a good company does not equate to being a good stock.   I hope I'm wrong.

[Trippedstocks]

dosage would have been advised by the DSMB by the Feb 26 PR. But as MF has stated, it's all confidential during the study. I don't see how they could apply for EUA without having results publicized. Who knows. I still would like to see the other IP progress as per their own set milestones in the public investors deck.

[1ottrunner]

The patients would have to know what the specifications of the trial were. They would have to be notified that they are getting X, Y, or Z. If the parameter changed at some point from Either X or Y or Z to either X or Y the patient would know. If the patient knows, we know. Thus why haven't we been notified that dosage has been determined? 2 options: 1. the trial hasn't decided on a

[Trippedstocks]

if results are good for the "worst" virus since the Spanish flu, why would you stop at that one virus. "Yep, got the big one... No way it will work on anything less infectious or less deadly." That's like saying a .30-30 wouldn't kill a skunk. Bit overkill but the bullets are cheap enough.